Market Insights
Autism, otherwise known as autism spectrum disorder, is a developmental disorder which affects cognitive function, social skills, and overall emotional & physical health of the afflicted individual. The disorder may occur at varying levels of severity and early identification is often a crucial step in treatment.
Market Research Future (MRFR) has recently published a report on the global Autism Disorder and Treatment Market Trends which reveals a steady CAGR of 4.37% during the forecast period 2017 to 2023. Gradual prevalence of autism, growing awareness, and the development of various forms of treatment for the disorder are some essential factors driving growth.
Advancing technology coupled with research and development of treatment options have provided scope for the autism spectrum infographic market to grow. With so many unanswered questions about autism, R&D is predicted to be the key motivator of growth for the global market. Other factors include rising awareness programs sponsored by government bodies and the increased availability of generic pharmaceuticals for affordable treatment.
Meanwhile, stringent regulations associated with product approvals are expected to hamper market growth. However, the unrealized potential of this market is likely to create opportunities. Additionally, stricter parameters for product approvals will likely lead the market to focus on genuinely effective treatment options.
Key Players
Analysis of the competitive landscape of the global autism disorder and treatment market includes prominent market players such as Consern Pharma Private Limited, Novartis AG, Johnson & Johnson Services Inc., Pfizer Inc., Eli Lilly and Company, Allergan, Merck & CO Inc., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Otsuka Holdings Co. Ltd., Intra-Cellular Therapies Inc., Saniona AB, Coronis Partners Ltd., Curemark LLC, and Heptares Therapeutics Limited.
Market Segmentation
The global autism spectrum infographic market has been evaluated by segments to provide conclusive insights regarding market growth. The market has been segmented on the basis of type, treatment type, drugs, and region.
By type, the market has been segmented into Asperger Syndrome, and Pervasive Developmental Disorder (PDD). PDD possesses the most significant market segment by type and is expected to witness a CAGR of 4.73% during the forecast period of 2017 to 2023.
By treatment type, the market has been segmented into Applied Behavioral Analysis (ABA), hyperbaric oxygen therapy, chelation therapy, and oxytocin therapy. Among these, the ABA segment is expected to achieve a CAGR of 4.82% during the forecast period.
By drug, the market has been segmented into SSRIs, anti-convulsant, stimulants, anti-psychotic. Anti-psychotics have been sub-segmented into Abilify (aripiprazole) and Risperidone. The anti-psychotic segment, which presently accounts for the largest segment by drug, is predicted to grow at a modest CAGR of 3.95% during the forecast period.
By region, the market has been segmented into the Americas, Europe, the Asia Pacific and the Middle East & Africa.
Regional Analysis
The Americas have the largest global market share, with North America leading market growth for the region. This is primarily due to the widespread awareness of the disorder which has increased early screening, thus facilitating market growth. Moreover, FDA approvals of atypical antipsychotics have further encouraged growth.
Europe closely follows the Americas’ lead and is expected to follow a similar growth pattern over the forecast period.
The Asia Pacific is the fastest growing global market share due to the increasing demand for treatment options and increased awareness of the disorder. Modern diagnostic tools and a better understanding of autism are expected to motivate significant growth for the region during the forecast period.
Meanwhile, the Middle East & Africa is expected to exhibit steady yet limited growth. This is due to the lack of awareness and social stigma associated with such disorders particularly in developing countries of the African region. Middle Eastern countries such as Qatar and the U.A.E, however, have schools and organizations dedicated to spreading awareness, this motivating steady growth for the region.
Latest Industry News
"We Rock the Spectrum" in New Jersey is a unique gym which has been created with the aim to provide a sensory safe space for children with autism and other developmental disorders. The equipment in the gym has been specially designed to cater to these children and provide them with a safe space.
The Food & Drug Administration (FDA) has given a fast-track designation to a drug which is designed to improve the core symptoms associated with autism. Still under development, the medication, L1-79, was fast-tracked after a small clinical study proved it's potential. The company behind this potentially revolutionary drug is Yamo Pharmaceuticals. Additional trials are planned.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
To stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
